African Trypanosomiasis-Associated Anemia: The Contribution of the Interplay between Parasites and the Mononuclear Phagocyte System

African trypanosomosis (AT) is a chronically debilitating parasitic disease of medical and economic importance for the development of sub-Saharan Africa. The trypanosomes that cause this disease are extracellular protozoan parasites that have developed efficient immune escape mechanisms to manipulate the entire host immune response to allow parasite survival and transmission. During the early stage of infection, a profound pro-inflammatory type 1 activation of the mononuclear phagocyte system (MPS), involving classically activated macrophages (i.e., M1), is required for initial parasite control. Yet, the persistence of this M1-type MPS activation in trypanosusceptible animals causes immunopathology with anemia as the most prominent pathological feature. By contrast, in trypanotolerant animals, there is an induction of IL-10 that promotes the induction of alternatively activated macrophages (M2) and collectively dampens tissue damage. A comparative gene expression analysis between M1 and M2 cells identified galectin-3 (Gal-3) and macrophage migration inhibitory factor (MIF) as novel M1-promoting factors, possibly acting synergistically and in concert with TNF-α during anemia development. While Gal-3 enhances erythrophagocytosis, MIF promotes both myeloid cell recruitment and iron retention within the MPS, thereby depriving iron for erythropoiesis. Hence, the enhanced erythrophagocytosis and suppressed erythropoiesis lead to anemia. Moreover, a thorough investigation using MIF-deficient mice revealed that the underlying mechanisms in AT-associated anemia development in trypanosusceptible and tolerant animals are quite distinct. In trypanosusceptible animals, anemia resembles anemia of inflammation, while in trypanotolerant animals’ hemodilution, mainly caused by hepatosplenomegaly, is an additional factor contributing to anemia. In this review, we give an overview of how trypanosome- and host-derived factors can contribute to trypanosomosis-associated anemia development with a focus on the MPS system. Finally, we will discuss potential intervention strategies to alleviate AT-associated anemia that might also have therapeutic potential.

African trypanosomosis (AT) is a chronically debilitating parasitic disease of medical and economic importance for the development of sub-Saharan Africa. The trypanosomes that cause this disease are extracellular protozoan parasites that have developed efficient immune escape mechanisms to manipulate the entire host immune response to allow parasite survival and transmission. During the early stage of infection, a profound pro-inflammatory type 1 activation of the mononuclear phagocyte system (MPS), involving classically activated macrophages (i.e., M1), is required for initial parasite control. Yet, the persistence of this M1-type MPS activation in trypanosusceptible animals causes immunopathology with anemia as the most prominent pathological feature. By contrast, in trypanotolerant animals, there is an induction of IL-10 that promotes the induction of alternatively activated macrophages (M2) and collectively dampens tissue damage. A comparative gene expression analysis between M1 and M2 cells identified galectin-3 (Gal-3) and macrophage migration inhibitory factor (MIF) as novel M1-promoting factors, possibly acting synergistically and in concert with TNF-α during anemia development. While Gal-3 enhances erythrophagocytosis, MIF promotes both myeloid cell recruitment and iron retention within the MPS, thereby depriving iron for erythropoiesis. Hence, the enhanced erythrophagocytosis and suppressed erythropoiesis lead to anemia. Moreover, a thorough investigation using MIF-deficient mice revealed that the underlying mechanisms in AT-associated anemia development in trypanosusceptible and tolerant animals are quite distinct. In trypanosusceptible animals, anemia resembles anemia of inflammation, while in trypanotolerant animals' hemodilution, mainly caused by hepatosplenomegaly, is an additional factor contributing to anemia. In this review, we give an overview of how trypanosome-and host-derived factors can contribute to trypanosomosisassociated anemia development with a focus on the MPS system. Finally, we will discuss potential intervention strategies to alleviate AT-associated anemia that might also have therapeutic potential.
Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 218 iNTRODUCTiON African trypanosomes are extracellular protozoan parasites causing debilitating diseases of medical, veterinary, and socio e conomical importance that adversely affect the economic develop ment of subSaharan Africa (1)(2)(3). The distribution of the disease coincides with the habitat of the tsetse fly vector (Glossina spp.), and is called the tsetse fly "belt" or is sometimes referred to as "green desert" due to the fact that ~10 million km 2 of potential fertile land is rendered unsuitable for cultivation (3). Within this area, the majority of the 39 tsetseinfested countries are underdeveloped, poor, heavily indebted, fooddeficit countries due to the lack of productive animals as far as meat/milk pro duction and draft power are concerned, resulting in an annual economic loss of about 5 billion US$ (4,5). In addition, about 60 million people living in this belt are at potential risk of infec tion with an estimated mortality rate of about 10,000 per year (6). Due to the low incidence of African trypanosomiasis, it is also considered a neglected disease. The disease caused by these extracellular hemoflagellates in humans is known as "sleeping sickness" or human African trypanosomiasis (HAT), while in domestic animals it is called "nagana" or animal African trypanosomiasis (AAT) (7). As far as HAT is concerned, two distinct subspecies of Trypanosoma brucei are responsible for the disease: (i) Trypanosoma brucei gambiense, typically found in western and central Africa (representing 98% of all cases, with humans as main reservoir), causes a chronic form of HAT (a few months to over several years) and (ii) Trypanosoma brucei rhodesiense, found in eastern and southern Africa [representing about 2% of all HAT cases due to the fact it is a zoonosis form with animals as main reservoir and humans being occasionally infected (8,9)], generally causes an acute form of HAT leading to death within a few months if left untreated (6,10,11). HAT is characterized by two successive stages: an early hemolymphatic stage, whereby the parasites are observed in the peripheral blood and the lymphatic system, and a later meningoencephalitic stage, where parasites cross the blood-brain barrier and proliferate in the cerebral spinal fluid resulting in neurological complica tions/cerebral pathology and death if left untreated (12,13). As far as AAT is concerned, the strictly intravascular parasites Trypanosoma congolense, as well as Trypanosoma vivax, can be considered the most important causative agents (14). Yet, also Trypanosoma brucei brucei and Trypanosoma evansi, residing both in intravascular as well as extravascular spaces within their host, have been documented to contribute to livestock infections (14)(15)(16). In contrast to game animals, where these parasites cause only mild infections, the disease in domestic animals is severe and often fatal (5,17,18). Various methods have been implemented to control African trypanosomiasis (19); including (i) vector control (20), (ii) reduc ing the proximity of livestock to reservoir hosts, (iii) development op trypanotolerant livestock (diseaseresistant breeds) (5,21), and (iv) using trypanocidal drugs (22). Yet, their success is lim ited due to the fact that these techniques are often used locally and not necessarily in a coordinated fashion (23), game animals func tion as parasite reservoir without exhibiting pathological signs (24), and the rapid emergence of drugresistant trypanosomes, thereby undermining their efficacy and leading to the widespread outbreaks of trypanosomiasis (19,25,26).
The main factor hampering control over African trypanoso miasis is the fact that these parasites have evolved very efficient immune escape mechanisms and are able to manipulate the entire host immune response to avoid elimination [reviewed in Ref. (27)]. Accordingly, an alternative approach to tackle African trypanosomiasis is targeting the infectionassociated immunopathology. For example, in HAT patients neurological complications are the major pathological feature, yet, an addi tional complication observed during the hemolymphatic stage is anemia (28,29). In AAT, anemia is considered the most prominent immunopathological diseaserelated feature and the major cause of death due to Nagana (30). Importantly, in cattle, trypanotolerance has been referred to as the capacity of an animal to control severe anemia development which is assumed to be independent of parasitemia levels (21,30). Moreover, Naessens et al. (31) showed using chimeric studies between trypanotolerant N'Dama (i.e., ancient cattle breeds/West African longhorn, Bos taurus) and trypanosusceptible Boran (more recently introduced cattle breeds, Bos indicus) that trypanotolerance is composed of two traits, (i) a better capacity to control parasitemia which is independent of the genetic origin of the hematopoietic tissue and (ii) a better ability to control anemia which is dependent on hematopoietic cells and thus a tolerant hematopoietic tissue genotype. Moreover, the capacity to control anemia is considered as the most important trait of the more resistant/trypanotolerant cattle (32). Yet, not only the genetic background (N'Dama versus Boran) but also other factors such as the age of the host, type of trypanosome spp. infecting, and nutrition can contribute to bovine trypanotolerance (33)(34)(35)(36)(37)(38).
Tsetse fly mediated (i.e., natural infection mode) and experi mental (i.e., using clonal parasites) murine models have been developed to allow a more detailed unraveling of the underlying mechanisms of trypanosomiasisassociated anemia develop ment. Although most trypanosomes cannot be considered natural pathogens for rodents, experimental infections in mice may offer good models to identify the molecular pathways that mediate particular traits or pathological features such as anemia (39). Moreover, the genetic background of the mice was also found to contribute to susceptibility or tolerance as far as anemia is concerned, whereby during T. brucei and T. congolense infec tion C57BL/6 mice exhibited severe anemia (yet low parasitemia) while BALB/c mice exhibited greatly reduced anemia (yet higher parasitemia) (40,41). However, there are some differences in the phenotype. Indeed, even the most tolerant mouse strains eventually succumb to the infection, while in the absence of other stress factors, tolerant cattle survive such challenge. So far, studies in murine models focusing mainly on "clonal or natural (tsetse transmitted)" T. congolense and T. brucei parasites have shown that similar as in the bovine system, chronic anemia does not seem to correlate with parasitemia or survival, but rather is a result of infectionelicited host responses, where Bcells do not seem to play a major role (40,42). By contrast, cells of the mono nuclear phagocyte system (MPS, i.e., tissue resident myeloid cells and inflammationelicited/inflammatory myeloid cells derived from circulating monocytes) have been shown to play a key role Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 218 in infectionassociated pathogenicity/anemia development (43). Moreover, due to their sensing ability towards pathogen and hostderived signals in the environment, their phagocytic capac ity and functional plasticity in response to these signals, cells of the MPS are considered as a crucial immune population in both health and disease. A large number of studies, including our work, have begun to establish how the ontogeny/differentiation of these cells is tailored during the course of African trypano some infections. In this review, we aim at (i) giving an overview of how trypanosomederived and hostderived factors can affect the MPS and contribute to trypanosomosisassociated anemia development and (ii) discussing on potential intervention strate gies to alleviate African trypanosomosis (AT)associated anemia that might also have therapeutic potential.

ANeMiA DeveLOPMeNT DURiNG AFRiCAN TRYPANOSOMe iNFeCTiONS
Myeloid Cells As Key Players in the Parasite-Host interaction and Trypanosomiasis-Associated Acute Anemia Development The interaction between African trypanosomes and their mam malian host elicits the sequential activation of innate and adaptive immune responses. Being extracellular parasites, they are con tinuously confronted with the host's immune system. However, through coevolution, a wellbalanced growth regulation system developed that allows sufficiently long parasite survival without killing its host to ensure transmission (44). This intricate balance consists of (i) a potent type 1 cellular/proinflammatory immune response and (ii) a strong humoral antiparasite Bcell response during the most prominent first peak parasitemia which col lectively allows parasite control and temporary host resistance (42,45). However, to avoid complete elimination, these extracellu lar parasites have developed various immune evasion mechanisms (consisting of antigenic variation, immunosuppression and Bcell depletion/loss of Bcell memory) to ensure progression/chronic ity and transmission (46)(47)(48)(49)(50). Moreover, the early "beneficial" proinflammatory immune response mediated by the activated MPS, can culminate into severe collateral damage to the host if persistent. In this context, the level of the inflammatory immune response triggered and the capacity of the host to control this response determines whether immunopathology (i.e., anemia and tissue damage) develops and allows discriminating between trypanosusceptible and trypanotolerant animals (see Figure 1). Experimental murine models, using genespecificdeficient animals, have been very crucial in trying to unravel the mecha nisms implicated in trypanosomiasisassociated pathogenicity and anemia in particular. In general, anemia occurs during all stages of a typical African trypanosome infection and can be divided into distinct phases (see Figure 1), (i) an early/acute stage whereby following/coinciding peak parasitemia clearance there is occurrence of a drastic drop in red blood cells (RBCs) numbers (i.e., acute or consumptive anemia) which is followed by a recovery phase and (ii) a more late/chronic phase coinciding with progressive anemia development. Accumulating evidence points to a pivotal role of myeloid cells in anemia development (see Figure 1). Hereby, their plasticity toward environmental triggers allows discriminating between classically activated macrophages (i.e., M1) and alternatively activated macrophages (i.e., M2). Moreover, the prevalence of M1 or M2 during the course of infection correlates with the severity of anemia (43). Consequently, both pro and antiinflammatory cytokines have been shown to be implicated in anemia onset and progression (51). In this section, different parasite and hostderived factors contributing to both myeloid cell activation and to acute and chronic anemia development will be discussed. To this end, two different murine African trypanosome models, i.e., the T. brucei and T. congolense infection model, will be compared. It is impor tant to mention that within the murine African trypanosomiasis model, T. brucei infections are associated with severe anemia (i.e., a more susceptible model) and T. congolense infections with reduced anemia (i.e., a more tolerant model). Emphasis will be put on the more thoroughly investigated murine T. brucei infec tion model. However, over the years more and more research has been conducted using the murine T. congolense infection model. Hence, we will also discuss, if possible, the common or distinct features underlying anemia development in both models.

Trypanosome-Derived Factors That Affect Myeloid Cell Activation during the Early/Acute Stage of Trypanosome Infection
Upon the bite of a trypanosomeinfected tsetse fly, metacyclic parasites expressing a heterologous variant surface glycoprotein (VSG) coat (i.e., metacyclic VSG) that prevents early detection/ elimination (52), are inoculated. Already during the early stage of infection, trypanosomes release factors that alone or in concert with saliva components can dampen/impair the activation of the host's immune response, to generate a privileged "micro" environment to allow infection establishment [reviewed in Ref. (27) and shown in Figure 2, left panel]. Of note, with respect to parasitereleased factors that could modulate the host MPS, most research so far has been performed using the model parasite T. brucei and remain to be determined for the T. congolense model. For instance, studies using the T. brucei model parasite revealed that they harbor a kinesin heavy chain 1 (TbKHC1), which induces IL10 and arginase1, signals through SIGNR1 in myeloid cells and downregulates inducible nitric oxide synthase activity (53). In turn, this stimulates the production by the host of lornithine and hereby the synthesis of polyamines, which promotes early parasite growth (54). Consequently, IL10/argi nase1producing immune cells are impaired in their capacity to destroy the parasite, favoring parasite settlement. Another factor trypanosomes use to establish infection is the T. brucei adenylate cyclase, which converts ATP into cyclic adenosine monophos phate (cAMP) and is upregulated upon phagocytosis by M1 cells (55). This phenomenon leads to the inhibition/suppression of macrophage activation and consequently to an impaired produc tion of parasite controlling molecules (56)(57)(58)(59). Hence, it seems that trypanosomes have developed a system, where altruistic phagocytosed parasites can "temporarily" tempering/disabling Anemia progression can be divided into (i) an acute phase characterized by a rapid drop in red blood cell (RBC) numbers (i.e., consumptive anemia) followed by a partial recovery phase, (ii) a late stage characterized in the susceptible model by a progressive decline in RBC numbers (below that of the acute phase) and host death. In the tolerant model, this decline is less pronounced and leads to (iii) a chronic phase (i.e., progressive anemia), whereby RBC numbers keep on declining till finally reaching levels of that of the acute phase. (B) Throughout the course of infection progressive hepatosplenomegaly occurs, whereby the onset of splenomegaly precedes hepatomegaly. At the late/ chronic stage of infection, splenomegaly is more pronounced than hepatomegaly. (C) During the different stages of infection, the host produces different mononuclear phagocyte system (MPS) polarizing molecules. During the early/acute stage, both trypanosusceptible (upper, green) and trypanotolerant (lower, blue) animals produce IFN-γ (green line) required to trigger the induction of classically activated macrophages (M1), which is followed by a moderate induction of IL-10 (blue line) to dampen the pathogenic effects of the M1. Only in the trypanotolerant model, there is a second progressive increase in IL-10 during the late/chronic phase of infection, which is required to induce alternatively activated macrophages (M2). (D) Occurrence of M1 and M2 during the course of aggressive Trypanosoma brucei or T. brucei attenuating strategies (GPI-based strategy or AAV-10/anti-CD28) or less virulent T. brucei PLC −/− /Trypanosoma congolense infection.
the M1mediated innate immune response required for parasite control (see Figure 2). In turn, this favors the induction of M2 and paves the way for initiation and establishment of the first wave of parasitemia.
Following initial infection, trypanosomes also "deliberately" trig ger in a welltimed manner host cellular responses, whereby myeloid cells get activated via the combined exposure of (i) parasitereleased components (i.e., pathogenassociated molecular patterns) such as the soluble and membranebound/glycosylphosphatidylinositol (GPI)anchored VSG (sVSG and mfVSG, respectively) and CpG DNA and (ii) NK/NKT/Tcell released IFNγ, which most likely is mediated via a trypanosomelymphocytetriggeringfactor (TLTF) (see Figure 2, right panel) (45,(60)(61)(62)(63)(64). This combination triggers the activation of M1 cells, which in turn release proinflammatory molecules such as tumor necrosis factor (TNFα) and nitric oxide (NO). However, the timing of exposure of these (parasite and hostderived) components is pivotal in the development of the immune response toward the parasites. These key events control ling host resistance occur within a short time period following initial exposure to the parasitederived components. Indeed, trypanosomes can cleave their GPIanchored VSG molecules from the membrane by the trypanosome GPIphospholipaseC, which results in the release of soluble glycosylinositolphosphate VSG (GIPsVSG) and the retention of the dimyristoylglycerol (DMG) moiety in the parasites' membrane (65)(66)(67)(68). Both components (DMG and GIPVSG) exhibit a distinct macrophageactivating FiGURe 2 | Proposed model for acute anemia development during trypanosome infections in trypanosusceptible animals (i.e., Trypanosoma brucei). During the early stage of infection, saliva components in concert with parasite-derived factors such as KHC [fueling parasite nutrient production (i.e., polyamines)] and AdC (dampening the potential of M1), temporarily disable/attenuate the M1-mediated innate immune response, thereby allowing parasite initiation/establishment. In addition, parasites release TLTF to trigger IFN-γ production by NK/NKT and CD8 + T cells, which will promote M1 cell activation. At the peak of parasitemia, these IFN-γ-primed M1 in concert with parasite-derived factors such as GPI-VSG (GIP/DMG) and CpG fuel M1 to produce pro-inflammatory molecules such as TNF, MIF, and Gal-3. In turn, TNF in concert with parasite-released extracellular vesicles (EVs) and/or sialidase trigger/enhance RBC senescence and hence erythrophagocytosis by M1 cells, leading to the development of acute anemia (i.e., hemophagocytic/consumptive anemia). Both MIF and Gal-3 promote M1 polarization and at this stage, there is an amplification of the iron homeostasis [i.e., increased iron storage (ferritin) and export (FPN-1)], which triggers extramedullary erythropoiesis. MIF also promotes recruitment/retention of mononuclear phagocytes and neutrophils, which in turn fuel the pathogenic effects of M1. At this stage, the host transiently produces IL-10, which is required to dampen the pathogenic effects of the M1 and in concert with the extramedullary erythropoiesis results in a partial recovery from acute anemia. Abbreviations: TLTF, T-lymphocyte triggering factor; KHC, kinesin heavy chain; AdC, adenylate cyclase; GPI, glycosylphosphatidylinositol; GIP, glycosylinosytolphosphate; RBC, red blood cell; MIF, macrophage migration inhibitory factor; Gal-3, galectin-3; FPN-1, ferroportin-1; Hemato, hematopoietic; Non-Hemato, non-hematopoietic; DMG, dimyristoylglycerol; VSG, variant surface glycoprotein.
potential (60,62). For example, the GIPVSG moiety is recognized by a type A scavenger receptor (SRA) expressed mainly on mononuclear cells (e.g., macrophages and dendritic cells) leading to the concentrationdependent activation of NFκB and MAPK pathways and expression of proinflammatory genes such as (TNF α, IL6, IL12p40, and granulocytemacrophage colonystimulating factor) in a MyD88 dependent manner (61,63). However, the fluctuating levels of parasite (e.g., GIPsVSG) and host (e.g., IFNγ) factors during infection act to control macrophage activity in a complex and subtle way, with the outcome determined by the concentration of each mediator, the sequential pattern of its pro duction, and the microenvironment of the target macrophage (69). For instance, during the early/initial stage of infection, the GIP sVSG released before a high level of IFNγ production prevents a prominent strong proinflammatory immune response and hence favors parasite establishment. Yet, if the IFNγ levels increase this will prime macrophages to respond stronger toward the parasite derived GIPsVSG, which in turn will fuel M1 cells to mount a prominent proinflammatory immune response.

Host-Derived Factors That Affect Myeloid Cell Activation during the Early/Acute Stage of Trypanosome Infection
Using genedeficient mice or neutralizing antibodies it was shown that the sequential production of IFNγ by NK, NKT, as well as CD8 + and CD4 + T cells during the early stage of trypanosome infection seems to be crucial to initiate acute inflammationassociated anemia (70), also termed consumptive anemia (71, 72) (see Figure 2, left panel). In this scenario, IFNγ activates M1 cells, which in turn allows parasite elimination/ removal, but at the same time also promotes the M1mediated enhanced uptake of RBCs resulting in a first rapid drop in RBC numbers. Indeed, IFNγ receptordeficient mice were found to exhibit greatly reduced acute anemia levels (73), coinciding with a reduced influx of myeloidderived cells, e.g., neutrophils and M1, within the liver that exhibit an impaired erythrophagocytosis capacity (70). Increased levels of hostderived IFNγ furthermore induce splenomegaly (71)   pHrodobased assay that during the early stage of T. brucei infec tion, CD11b + Ly6G + neutrophils, CD11b + Ly6C high monocytic cells, as well as splenic CD11b + F4/80 + myeloid cells exhibit an enhanced erythrophagocytosis capacity that might account for the occurrence of severe acutestage nonhemolytic anemia. Interestingly, it was shown by others that enhanced erythropha gocytosis is associated with the mobilization of Ly6C high mono cytes in a CCR2dependent manner from the bone marrow into the blood (75), which accumulate mainly within the liver and subsequently ingest stressed/senescent erythrocytes. These cells differentiate into ironrecycling/ferroportin1 (FPN1, sole iron exporting molecule)expressing tissue macrophages and subsequently into ironrecycling Kupfferlike cells, which is a natural mechanism to preserve homeostasis during fluctuations of erythrocyte integrity (76).

Host-and Parasite-Derived Factors That Contribute to Acute Anemia
It was shown that RBCs from infected (i.e., day 6 postinfection) wildtype (WT) mice exhibited an enhanced osmotic fragility and an altered fatty acid membrane composition compared with RBCs from noninfected WT mice (70). This change in RBC fragility was not due to IFNγ but might be due to hostderived factors such as TNFα produced by M1 cells (77)(78)(79)(80). Indeed, TNFα could be a driving force for the observed changes in RBC fragility given that it was shown that it can decrease the RBC halflife and thereby fuel RBC senescence/elimination (81). The importance of host derived factors such as TNFα in acute anemia development was further substantiated by the observation that T. bruceiinfected TNFαdeficient (TNFα −/− ) mice exhibited greatly reduced acute anemia levels compared with control WT mice (see Table 1). Thereafter, RBC levels in TNFα −/− mice remained elevated. By contrast, in the T. congolense model, TNFα −/− mice exhibited similar acute anemia (and chronic) levels as control WT mice (82,83), suggesting that in this model the underlying mechanisms of anemia development are different. Besides TNFα produced by activated myeloid cells, NO was also found to be an important factor affecting T. bruceiassociated acute anemia development. Indeed, treating C57BL/6 mice with lNAME (a typical inhibitor of NO synthase) alleviated acute anemia development (coincid ing with reduced peak parasitemia) and was proposed to affect proliferation of immature erythrocytes or hematopoietic stem cells (73,84). In line with these observations, mice treated with corticosteroids (which downregulates NO synthesis) exhibited an alleviated anemia development (85). However, more research is required to unravel at which level NO affects T. bruceiassociated acute anemia development.
Also parasitederived factors such as sialidases in the case of T. congolense or extracellular vesicles (EVs) in the case of T. brucei infections could contribute to modifications of RBCs and thereby promote elimination (77)(78)(79)(80). Indeed, it was pro posed at least for the murine T. brucei model that during the acute stage, trypanosomes release EVs (filled with intracellular parasite cargo as well as VSG) that can fuse with RBCs. This causes a change in the physical properties of the RBC membrane, which enhances erythrophagocytosis and thereby fuels anemia development. In this context, it could be that binding of mfVSG (present in the EVs) to the RBC surface sensitizes erythrocytes to antiVSG antibodymediated complement lysis (86). In addition, this observation might also explain how active adenylate cyclase, playing a key role in increasing cAMP in host cells resulting in the activation of protein kinase A and downregulation of TNFα, could be transferred from the parasite to the mammalian host (see above). Indeed, the highly fusogenic EVs containing this enzyme might be transferred to recipient host cells, thereby increasing the intracellular levels of cAMP. Given that these EVs are mainly produced at the peak of parasitemia, they might in one way stimulate RBC elimination and at the same time dampen sub sequent inflammatory reactions, thereby allowing the next wave of parasites to escape. Also for the murine and bovine T. congolense model, factors such as congopain and sialidases were suggested to contribute directly/indirectly to anemia deve lopment, by damaging RBCs that results in the exposure of erythrophagocytosis promoting targets (phosphatidylserine) on the RBC membrane (78,87,88).
Different factors might account for the occurrence of acute anemia in both the T. brucei as well as the T. congolense murine infection model. Hence, the acute stage of anemia could be due to a "natural" reaction of the host following infection as well as to parasitederived factors resulting in a rapid drop in RBC numbers due to enhanced erythrophagocytosis (89). At this stage of infection, due to the enhance erythrophagocytosis, there is an amplification of the ironhomeostasis metabolism (90), resulting in an increased release of iron to fuel the enhanced demand for erythropoiesis (Figure 2, right panel). Transition from Acute to Chronic Anemia: The Recovery Phase Following this acute anemia phase, there is a transient recovery phase in both the T. brucei as well as the T. congolense infec tion model (see Figure 1), as a natural response of the host to control/alleviate acute anemia development. Of note, within the T. brucei infection model, this recovery was more pronounced in the IFNγR −/− , CD8 −/− , TNFα −/− , and TNFR2 −/− mice, sug gesting that a reduced early proinflammatory response/insult allows better recovery from acute anemia. However, so far, the exact mechanism(s) involved are not well characterized. From other experimental models of acute anemia (phenylhydrazine induced injection or bleeding), it could be inferred that this is most likely due to an enhanced extramedullary erythropoiesis occurring mainly in the spleen and to a lesser extent in the liver and coincides with the occurrence of hepatosplenomegaly. In this context, both in the T. brucei and T. congolense infection model, hepatosplenomegaly has been documented starting already dur ing the early stages of infection, and coincided with an increase in immature RBC numbers within the splenic compartment (91)(92)(93)(94)(95).
It is generally known that anemia induces tissue hypoxia, which in turn triggers the activation of a physiological stress response (i.e., stress erythropoiesis) designed to increase oxygen delivery to tissues by rapidly generating large numbers of erythrocytes (96). Moreover, tissue hypoxia triggers the induction of erythropoietin (EPO) in the kidney (97), which drives the expansion and dif ferentiation of erythroid progenitors. Of note, during murine and bovine trypanosome infections, serum EPO levels are increased during both the acute and chronic stage of infection (83,98). Subsequently, the bone marrow progenitor cells migrating into the spleen or stress erythroid progenitors resident in the spleen expand and differentiate in response to bone morphogenetic protein 4 (BMP4) and Hedgehog, which act in concert with signals previously associated with stress erythropoiesis, such as EPO, stem cell factor and hypoxia, to replenish the pool of stress erythroid progenitors (96,99,100). Whether macrophages play also a role at the level of erythropoiesis within the African trypanosome model remains to be further investigated. However, it was shown that upon anemia or stress, macrophagedependent erythropoiesis (within erythroblastic islands) is needed to adequately respond to produce enough erythrocytes to allevi ate the shortage (101,102). Interestingly, in experimental T. congolense infections in rats, erythroblastic islands were found to expand already during the early stages of infection within the bone marrow (103). It is important to mention that following this prominent proinflammatory immune response and coincid ing with the partial recovery of acute anemia, the host is able to trigger a "transient" antiinflammatory immune response, whereby IL10 was shown to play a key role (104,105). At this stage, CD4 + T cells were shown to be important IL10producing cells to dampen the pathogenic effects of the IFNγinduced M1 (106). Yet, it can not be excluded that other cells (hematopoietic or nonhematopoietic) might also contribute (see Figure 2, right panel). Recently, it was also suggested that IL27 can play a key role in dampening the pathogenic effects of T cellmediated IFNγ during T. brucei and T. congolense infection without affect ing IL10 levels (107).

Myeloid Cells As Key Players during the Late/Chronic/Progressive Stage of Trypanosomiasis-Associated Anemia Development
Following partial recovery from acute anemia, there is a new equilibrium established, which is different from the steadystate situation (see Figure 1). At this stage, the capacity of the host to keep the balance between erythrophagocytosis and eryth ropoiesis determines whether anemia persists. This also allows discriminating between susceptible and tolerant animals as far as anemia is concerned, whereby the activation stage of the myeloid cells determines the degree of anemia. Indeed, on one hand, trypanosusceptible animals maintain a prominent/polarized M1 activation state and exhibit progressive anemia (i.e., T. b. brucei model), which resembles anemia of chronic disease or anemia of inflammation (90). This is characterized by an enhanced erythrophagocytosis and impaired/reduced erythropoiesis that is linked to a perturbed iron homeostasis including altered iron recycling by macrophages and iron sequestration (Figure 2). Therefore, the ironprocessing pathway is skewed toward iron sequestration (40,90), as evidenced by increased ferritin expres sion (main iron storage molecule) and reduced FPN1 (sole iron exporter), while enhanced uptake of RBC/ironcontaining compounds is maintained (see Figure 3, left panel). Moreover, iron sequestration by cells of the MPS can fuel their M1type activation status and limit iron availability for erythropoiesis (108)(109)(110)(111), thereby contributing to the persistence of anemia. In this context, it was shown that proinflammatory cytokines such as IFNγ, TNF, IL1, and IL6 can affect ironhomeostasis regulation as well as erythropoiesis. Indeed, during homeostasis, there is a balance between RBC destruction and production, where the iron availability is adequate to accommodate the host's erythropoietic demand (112). Yet, during inflammation this balance is shifted toward an enhanced RBC destruction and impaired/insufficient production or RBCs, leading to anemia. These proinflammatory cytokines trigger (i) the upregulation of the divalent metal transporter1, which increases iron uptake by the reticuloendothelial cells, (ii) an enhanced ferritin expression (i.e., iron storage molecule), and (iii) a downregulation of FPN1 expression thereby promoting iron retention within the MPS (113,114). This will cause a deprivation of iron from erythropoiesis. At the same time, these proinflammatory cytokines inhibit eryth ropoiesis by (i) downregulating EPO receptors thereby impairing the EPOmediated effects, (ii) increasing erythroid apoptosis, and (iii) antagonizing prohematopoietic factors (115,116).
On the other hand, trypanotolerant animals are able to switch to a protective antiinflammatory response (induced via IL10), which is reflected by the occurrence of M2 cells that in concert with IL10 are able to dampen the pathological effects of the M1 cells, and exhibit an alleviated anemia development [i.e., T. brucei atte nuation strategies, phospholipaseCdeficient (PLC −/− ) T. brucei and T. congolense model]. Moreover, trypanotolerant animals in contrast to trypanosusceptible animals exhibit a restored iron homeostasis (i.e., an enhanced FPN1 and reduced ferritin expression) and increased iron availability for erythropoiesis (95). In addition, M2 cells exhibit a reduced erythrophagocytosis  Figure 2), trypanosusceptible animals are unable to trigger a second wave of IL-10 production resulting in persistence of M1, which is most likely promoted via macrophage migration inhibitory factor (MIF) and galectin-3. These M1 produce TNF that further promotes erythrophagocytosis and exhibit iron accumulation [increased ferritin and reduced ferroportin-1 (FPN-1) expression], resulting in iron deprivation from erythropoiesis and collectively leading to progressive anemia development. MIF also promotes myeloid cell recruitment/retention leading to liver injury. By contrast, in trypanotolerant animals, following the acute stage of infection, hematopoietic (hemato) or non-hematopoietic (non-hemato) cells produce IL-10, which dampens the pathogenic effects of the M1 by triggering the induction of M2. These M2 exhibit reduced erythrophagocytosis and reduced iron retention, leading to a more efficient erythropoiesis and in turn to reduced progressive anemia development. IL-10 also reduces liver injury by dampening the pathogenic effects of the M1. (Right panel) However, the chronic production of MIF by M1 and persistent IL-10 production can collectively promote progressive hemodilution, which is most likely due to enhanced (hepato)-splenomegaly. In turn, the hemodilution will cause an apparent anemia development in trypanotolerant animals, resulting in thrombocytopenia and impaired coagulation in infected mice. The heme catabolism following the chronically induced erythrophagocytosis leads to iron accumulation in myeloid cells and to hyperbilirubinemia. The combination of liver injury and hemodilution leads to declined serum albumin levels, thereby preventing efficient removal of toxic molecules from the circulation, including bilirubin, and cause multiple organ failure that culminates in reduced survival of the infected host. capacity, whereby iron homeostasis is skewed toward export (117). It is important to mention that in both the T. brucei and T. congolense infection model, the host is able to produce IL10 during the acute stage of anemia to dampen the pathogenic effects mediated via the pronounced proinflammatory response, which is linked to the first wave of parasitemia control. However, it seems that in the T. brucei (susceptible) model the host is unable to retrigger IL10 induction to dampen the second wave of inflammation, while in the PLC −/− T. brucei/T. congolense (tolerant) model the host is able to mount a second progressive IL10 response, which is sufficient to dampen the lower level of inflammation. This difference in ability to trigger a second wave of IL10 (or alternatively, maintain an IL10 triggering potential) is also reflected at the level of differences in M1 and M2 between susceptible and tolerant animals.

Myeloid Cell Activation in the T. brucei (Susceptible) versus T. congolense (Tolerant) Model
As far as the T. brucei model (using AnTat1.1E) is concerned, there is a persistent M1 activation contributing to severe anemia and tissue injury (see Figures 1 and 3). It was shown that the TNFfamily members [TNFα and lymphotoxinalpha (LTα)] play a key role in chronic/progressive anemia develop ment by signaling via their dedicated receptors [TNFR1 or p55 (CD120a), TNFR2, or p75 (CD120b)] (see Table 1) (118). Thus, TNFαdeficient (TNFα −/− ) or TNFR2deficient (TNFR2 −/− ) mice exhibited greatly reduced chronic anemia compared with WT or TNFR1deficient (TNFR1 −/− ) mice (41,59), suggesting that TNFR2 signaling mediates infectionassociated pathol ogy, whereas TNFR1 signaling has little or no impact on the T. brucei infection. Moreover, the serum levels of soluble TNF R2 after shedding, which impaired TNFαsignaling pathways in myeloid cells, correlated with the inhibition of TNFmediated immunopathology. Moreover, the low ratio of total TNFα to soluble TNFR2 observed in BALB/c mice may account for the lack of TNFmediated pathology, whereas an increased ratio in C57BL/6 mice coincided with the severe pathology/ anemia. Using LTα −/− mice, it was shown that the TIP sequence (i.e., lectinlike domain) of TNFα does not seem to play a role in anemia development (118). Importantly, TNFα and LTα Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 218 have high amino acid sequence homology and both bind to the TNFα p55 and p75 receptors (TNFR1 and R2, respectively) as soluble homotrimers (119), yet they exhibit alterations in the TIP sequences (120). For example, TNFα exerts a lectinlike affinity for several carbohydrate sequences while LTα does not (121). These LTα −/− mice were shown to exhibit during the middle stage of infection (days 10-28) a greatly reduced anemia compared with WT mice, which coincided with reduced TNFα induction in LTα −/− mice during this stage. However, during the final stage of infection, serum TNFα reaches the same levels in both LTα −/− and WT mice, concomitant with similar anemia levels in both mice groups. A possible explanation for this might be that TNFα is also an important negative regula tor of erythropoiesis and this aspect might predominate at later stages of infection (51,122). Hence, strategies to reduce TNF signaling or allowing switching from M1 toward M2 might also be valuable to alleviate chronic anemia development. Different factors were found to contribute to the ability of the host to switch from M1 to M2 and the ability to maintain/trigger IL10 during the later stages was shown to be detrimental to attenuate anemia.
Collectively, it seems that the mechanisms underlying trypa nosomiasisassociated anemia are multifactorial and the relative contribution of each mechanism will differ according to the host-parasite model, the phase of anemia development and the severity of infection and is probably caused by massive extravascular erythrophagocytosis by an expanded MPS in con cert with an inadequate erythropoiesis.

POTeNTiAL iNTeRveNTiON STRATeGieS TO ALLeviATe AT-ASSOCiATeD ANeMiA
The Parasite Strain Used Determines the MPS Activation State and Anemia Development Typically, in the experimental T. brucei C57BL/6 model, the myeloid cells are polarized into an M1 state, which is pro moted due to the inability of the host to sustain a strong anti inflammatory immune response. By contrast, in the less aggres sive model experimental PLC −/− T. brucei C57BL/6 model, there is a switch from M1 toward M2 mediated via IL10, coinciding with reduced pathology (anemia/tissue injury) and prolonged survival. A possible explanation for this switch toward M2 in the PLC −/− T. brucei model and not in the WT T. brucei model might rely in the fact that the PLC is required to sustain M1 by (i) allowing the release of GPIanchored proteins (encom passing the GIP) to stimulate macrophages to secrete pro inflammatory molecules (TNFα, IL1, IL6, and NO) and/or (ii) trigger CD1drestricted NKT cells to secrete IFNγ thereby triggering a very strong type 1 immune response (60,123). Indeed, it was shown that in the PLC −/− T. brucei C57BL/6 model the lower parasitemia coincided with reduced early IFNγ production and subsequent attenuated MPSderived proinflammatory cytokine production, reflecting a reduced type 1 immune response mounted (124)(125)(126). The crucial role of IFNγ and IL10 during infection was further substantiated using genedeficient mice, where the absence of IL10 coin cided with high pathology and early mortality. Although the source of IL10 was not thoroughly investigated within the PLC −/− T. brucei model, some data suggest the involvement of CD4 + T cells (124). Interestingly, infections of PLC −/− T. brucei parasites using C57BL/6 x BALB/c (B6BF1) mice were found to exhibit striking similarities with that of the trypanotolerant N'Dama cattle naturally infected with T. congolense. These latter include (i) lower parasitemia, (ii) prolonged survival, (iii) increased type II and decreased type I immune responses, and (iv) reduced pathology and minimal clinical symptoms during the course of infection (127,128). Therefore, PLC −/− T. bruceiinfected B6BF1 mice represent a suitable model to study the immune responses during bovine T. congolense infec tions. Within the T. congolense model in C57BL/6 mice, it was shown that spleen and liver regulatory T cells (Foxp3 + Tregs) were an important source of IL10, thereby limiting the produc tion of early IFNγ by T cells and in that way lowering patho logy. Besides Tregs, also myeloidderived IL10 was shown to play an important role in limiting the production of pathogenic TNFα by M1 cells (characterized as CD11b + Ly6C + ) through induction of nuclear translocation of the NFκB p50 member (129). However, it cannot be excluded that other hematopoietic and nonhematopoietic cells can be potential sources of IL10 during the course of T. congolense infection (Figure 3).

iL-10-inducing Strategies to Modulate the MPS Activation State and Anemia Development
As mentioned before, the capacity of the host to induce IL10 immediately after the induction of a prominent proinflammatory immune response mediated via M1 cells determines whether pathology/anemia develops/is alleviated or not. This opens per spectives for potential IL10 triggering/promoting intervention strategies aiming at triggering an M1 toward M2 switch, thereby reducing pathology development. So far, several strategies have been used to demonstrate/strengthen the pivotal role of IL10 in reducing trypanosomiasisassociated pathogenicity using the susceptible T. brucei model. For instance, transient antiCD28 superagonist antibody treatment (inducing regulatory T cells and M2) in the T. brucei model attenuated acute anemia development (130). Given that this treatment was not continued during the chronic phase of infection its effects during this stage remain to be determined. Alternatively, adenoviral delivery of IL10 in the T. brucei model coincided with an alleviated pathology/ anemia development (131), during the chronic phase of infection (see Table 1). Also a GPIbased treatment strategy, where the parasitederived GPI moiety (i.e., most potent parasitederived TNFinducing molecule involved in M1 triggering) was used to reprogram macrophages toward an antiinflammatory state (i.e., reflected by a reduced inflammatory cytokine production and increased IL10 production), was shown to alleviate anemia in both clonal as well as natural/nonclonal T. brucei infections (132). This strategy allowed reducing RBC destruction, normal izing iron homeostasis (i.e., a shift in increased liver expres sion of iron storage toward iron export genes) and restoring MPS and Trypanosomiasis-Associated Anemia Frontiers in Immunology | www.frontiersin.org February 2018 | Volume 9 | Article 218 erythropoiesis [i.e., increased erythropoiesis in the bone marrow and extramedullary sites (spleen)] (95). Interestingly, this GPI based treatment also alleviated "chronic" anemia development during experimental T. congolense as well as T. evansi infections suggesting a wide applicability.

M1-Promoting Factors Are Prime Targets to Attenuate Anemia
Given that M1 cells are major contributors to anemia develop ment, identification of M1derived pathological factors might open perspectives to attenuate the pathology. An approach to identify potential M1derived pathology inducing/promot ing factors consisted of scrutinizing a GPIbased strategy, which enabled a straightforward comparison between tryp anotolerance and trypanosusceptibility in T. bruceiinfected C57BL/6 mice, independent of the genetic background of the host (95). A resulting comparative gene expression analysis of M1polarizing molecules and/or molecules involved in enhancing erythrophagocytosis identified galectin3 (Gal3) and macrophage migration inhibitory factor (MIF) as potential candidates. Both molecules were indeed found to contribute to anemia development during T. brucei infections by affecting/ regulating different aspects of the host's immune response. As far as Gal3 (i.e., a family member of betagalactosidebinding animal lectins) is concerned, it was shown that Gal-3 −/− mice manifested higher IL10 levels that can exert an influence on iron uptake and counteract the effects of IFNγ (133). Hence, Gal3 can promote persistence of M1 and regulate the expres sion of ironhomeostasis genes, favoring iron storage, which ultimately culminates in iron shortage for erythropoiesis and exacerbate inflammationassociated anemia development (Figures 2 and 3) (133,134). In addition, given the negative effect of Gal3 on the induction of IL10, a persistent inflam matory response is ensured in presence of Gal3. As far as MIF is concerned, this "early response" cytokine is expressed by numerous cell types, including myeloid cells, plays a key role in innate and adaptive immunity and was shown to be involved in many protozoan infections (135)(136)(137). Using Mif −/− mice it was shown that this upstream regulator of the inflammatory cascade contributed to inflammationassociated pathogenicity by (i) sustaining a persistent proinflammatory type I immune response (impairing IL10 production) and (ii) maintaining/ enhancing the recruitment of pathogenic monocytic cells and neutrophils in the liver whereby neutrophilderived MIF con tributed significantly to enhanced TNF production and liver damage (Figures 2 and 3) (93). The pivotal role of MIF within the African trypanosomiasis model regarding the persistence of inflammation might be multifactorial. For instance, endoge nous MIF has been shown to (i) promote macrophagemediated inflammatory responses via induction of CC chemokine ligand 2 expression, thereby promoting the recruitment of monocytes into affected areas and (ii) exert a regulatory role in cellular responsiveness to key proinflammatory cytokines TNF and IL1 via upregulation of cytokine receptordependent MAPK signaling (i.e., upregulation of TNFR1 and IL1R expression, respectively) independent of NFκB (138,139). Hence, by both attracting and activating monocyte/macrophages, MIF may contribute to the initiation and perpetuation of detri mental inflammation associated with diseases such as African trypanosomiasis. In addition, MIF importantly contributed to anemia development by (i) promoting iron accumulation in liver myeloid cells, (ii) enhancing RBC clearance, and (iii) suppressing erythropoiesis at later stages of erythroblast differentiation (Figure 3) (93). Interestingly, MIF was also shown to be a potential pathogenic molecule playing a key role in chronic anemia development during T. congolense infections by (i) promoting erythrophagocytosis, (ii) blocking extramed ullary erythropoiesis and RBC maturation, and (iii) triggering hemodilution (Figure 3) (94).
Overall, it seems that during murine T. brucei and T. congolense infections anemia is mainly due to enhanced erythrophagocy tosis combined with enhanced but inadequate extramedullary erythropoiesis. Yet, during T. congolense but not T. brucei infec tions, hemodilution (involving massive hepatosplenomegaly) seems to be an additional factor contributing to chronic anemia development (93,94). However, it might be that within the T. brucei model the contribution of hepatosplenomegaly to hemodilution is minor or not reached within this "short" time period. This notion is strengthened by the fact that there was no correlation between anemia and hemodilution (involving hepatosplenomegaly) in T. brucei and T. congolenseinfected rats within the same time window (92). However, a different T. brucei parasite strain (TREU 667 strain) causing a more chronic infection involving also revealed that the hepatosple nomegaly could contribute to hemodilution (140). Of note, also in HAT patients exhibiting anemia during later stages of the disease, hepatosplenomegaly has been recorded and this might therefore contribute to the observed "apparent" anemia (28). In this particular model, it seems that the virulence of the parasites determines whether hemodilution occurs. Interestingly, these observations correlate nicely with experimental T. brucei and T. congolense infections in domestic animals (cattle and sheep, respectively) (141,142). Importantly, it was shown that MIF can also be present in erythrocytes and upon (hemo)lysis, due to oxidative stress, this factor can be released to further fuel inflammation (143). Given that hemolysis was shown to occur during T. congolense infections (40,144), the increased levels of MIF observed during both the acute and chronic stage might mainly be due to parasiteinflicted rather that hostmediated damage of RBCs, which could also fuel a chronic (lowgrade) anemia profile. Therefore, MIF might be an "important" player (upstream regulator) in African trypanosomiasisassociated anemia, mainly during the chronic stage of anemia development by fueling/promoting pathogenic M1 and could be considered as a prime antidisease target.

GeNeRAL CONCLUSiON AND PeRSPeCTiveS
African trypanosomes are very proficient in sculpturing a temporal environment to allow a gradual parasite establish ment (27). Hereby, the host's response at different stages of the infection determines whether pathogenicity/anemia develops. The mechanisms underlying African trypanosomiasisassociated anemia are multifactorial, whereby various molecules influ ence differentially the progression/development of anemia at distinct stages of infection. Initially, acute anemia seems to develop as part of the innate immune response upon infec tion, where parasitederived factors, such as parasitederived EVs, as well as hostderived (parasiteinduced) IFNγ trigger M1 cell differentiation that in turn produce proinflammatory molecules to control the infection. In this context, IFNγ produced at the acute stage is the driving factor leading to acute/hemophagocytic anemia (30). In addition, the release of parasitederived EVs in concert with hostderived TNFα affect RBC survival and thereby fuels RBC elimination trough erythrophagocytosis (Figure 2). This is followed by a partial recovery, mediated most likely via extramedullary erythropoie sis, as a homeostatic reaction and a transient IL10 production to dampen the pathogenic effects of the M1. Depending on the level of insult (i.e., M1induced damage) and the capacity of the host to trigger and subsequently maintain IL10 production, anemia is either alleviated (i.e., trypanotolerant animals) or sustained (i.e., trypanosusceptible animals). At this stage, MIF is an important hostderived factor determining/regulating the progression of anemia by promoting a persistent pro inflammatory immune response and suppressing erythro poiesis. In addition, IFNγ, TNFα, and MIF are important molecules exerting a negative effect on erythropoiesis and at the same time at promoting erythrophagocytosis. By contrast, IL10 was shown to positively affect erythropoiesis by down regulating the effects of the proinflammatory cytokines (145). Therefore, the balance between these pro and antiinflam matory cytokines during the course of infection determines the course of anemia development (51). In other words, the ability of the host to mount an efficient erythropoietic response (stressinduced response) to compensate for the enhanced erythrophagocytosis determines whether anemia persists. In the murine model, but also in cattle, the erythropoietic poten tial determines the level of anemia (33,40,94,122). However, it seems that chronic anemia is most likely hostinflicted and due to a disproportional immune response (30). In summary, the mechanisms underlying/promoting chronic anemia deve lopment during T. brucei and T. congolense infections seem to be different. In the T. brucei infection model the main driving forces for anemia development are (i) the persistence of M1 that promote enhanced RBC elimination and iron retention and (ii) an insufficient erythropoiesis due to iron deprivation and the presence of proinflammatory cytokines that suppress RBC differentiation/maturation (Figure 3). By contrast, in the T. congolense infection model these aspects seem to play a main role only during the acute stage, as once M2 are induced and expanding they can in concert with IL10 dampen to a certain extent the pathogenic effects of the M1. Given that T. congolenseinfected animals still exhibited chronic anemia despite the presence of M2 and IL10 suggests that the under lying mechanisms of chronic anemia in this model might be different and might rely on the hematopoietic potential of the animals (40). It was proposed that the monthlasting lowgrade inflammatory response can also drive erythrophagocytosis, where the ensuing catabolism of hemoglobin resulted in iron accumulation mainly in the spleen and is followed by the enhanced release of bilirubin in the blood circulation (94). The resulting hyperbilirubinemia could favor the externalization of phosphatidylserine on RBCs and thus further contribute to erythrophagocytosis or eryptosis during T. congolense infection (146). However, at this stage the persistence of IL10 might be a doubleedged sword by on one hand dampening tissue injury and reduce the suppression on erythropoiesis mediated by the M1released proinflammatory mediators and on the other promoting (i) ferritin expression thereby indirectly affecting iron availability, (ii) thrombocytopenia, and (iii) splenomegaly, leading to hemodilution (147,148). The latter might in turn culminate into the occurrence of appar ent anemia development, despite an enhanced erythropoiesis activity. In this context, it was shown that sustained secretion of IL10 from transduced muscle leads to thrombocytopenia and splenomegaly in mice injected with rAAV1IL10 (147). Interestingly, thrombocytopenia was also documented for T. congolenseinfected animals (149,150). The splenomegaly observed in both susceptible and tolerant animals is required to accommodate the increased demand for erythropoiesis (93)(94)(95). However, it seems that this excessive accumulation of immature RBCs is most likely due to an inefficient erythropoi etic potential (e.g., iron retention or unresponsiveness toward EPO or inefficient functioning of erythroblastic islands). Indeed, it was shown that most genes involved in erythropoiesis were found to be significantly modulated during the course of both T. brucei and T. congolense infection (40,93,94). However, so far information regarding erythropoiesis during African trypanosomiasis is limited and requires more attention. Also, a possible involvement of macrophages (functionality) within erythroblastic islands requires consideration. Within the era of genomics/proteomics (151)(152)(153)(154), we can assume that novel pathways, mechanisms and molecular target molecules will be identified in various mouse models (155,156). These discover ies will help us to refine our understanding of the mechanisms underlying anemia development and could even pave the way to develop new intervention strategies to alleviate it.

AUTHOR CONTRiBUTiONS
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDiNG
The authors acknowledge the financial support of the Inter university Attraction Pole Program (PAIIAP N. P7/41, http:// www.belspo.be/belspo/iap/index_en.stm) and grants from the FWO (FWO G015016N and G.0.028.10.N.10). BS is a research fellow supported by the Strategic Research Program (SRP3, VUB): targeting inflammation linked to infectious diseases and cancer (Nanobodies for Health). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.